FT. MYERS, Fla., Nov. 7 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. announced today that President and Chief Scientific Officer, Bob Gasparini, will present at the Rodman & Renshaw 10th Annual Healthcare Conference being held from November 10-12, 2008 at the New York Palace Hotel in New York City. The conference will showcase over 350 small and microcap public life sciences and biotech companies. Gasparini and other senior executives of attending companies will make presentations to portfolio managers and analysts on their business strategy and outlook. One-on-one meetings with interested parties will also be arranged during the three-day conference.
NeoGenomics is scheduled to present on Monday, November 10th at 5:20 PM EST. A live audio webcast of the presentation can be accessed at http://www.wsw.com/webcast/rrshq14/ngnm.ob . A PowerPoint presentation and a link to the webcast can also be accessed through the investor relations section of the NeoGenomics website at http://www.neogenomics.org at the time of the conference. The webcast will be available for three months.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org .
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company’s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company’s periodic filings with the SEC.
CONTACT: Investors, Steven C. Jones, Director of Investor Relations of
NeoGenomics, Inc., +1-239-325-2001, sjones@neogenomics.org; or Julie
Marshall, Hawk Associates, Inc., +1-305-451-1888, Info@hawkassociates.com
Web site: http://www.neogenomics.org/
http://www.hawkassociates.com/
